AR044502A1 - Quinazolinas utiles como moduladores de canales ionicos - Google Patents

Quinazolinas utiles como moduladores de canales ionicos

Info

Publication number
AR044502A1
AR044502A1 ARP040100670A ARP040100670A AR044502A1 AR 044502 A1 AR044502 A1 AR 044502A1 AR P040100670 A ARP040100670 A AR P040100670A AR P040100670 A ARP040100670 A AR P040100670A AR 044502 A1 AR044502 A1 AR 044502A1
Authority
AR
Argentina
Prior art keywords
ring
phenyl
unsubstituted
taken together
optionally substituted
Prior art date
Application number
ARP040100670A
Other languages
English (en)
Inventor
Jesus E Gonzales Iii
Dean Mitchell Wilson
Andreas Peter Termin
Peter Diederik Jan Grootenhuis
Yulian Zhang
Benjamin John Petzsoldt
Lev Tyler Dewey Fanning
Timothy Donald Neubert
Roger D Tung
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR044502A1 publication Critical patent/AR044502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se provee también composiciones farmacéuticamente aceptables y métodos para usar las composiciones en el tratamiento de varios trastornos. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: R1 y R2, tomados conjuntamente con el átomo de nitrógeno al cual están ligados, forman un anillo monocíclico o bicíclico de 3-12 miembros opcionalmente substituido saturado, parcialmente no saturado, o completamente no saturado que tiene de 0-3 heteroátomos adicionales seleccionados independientemente entre nitrógeno, azufre, u oxígeno; donde el anillo formado por R1 y R2 tomados conjuntamente, es opcionalmente substituido en uno o más átomos substituibles de carbono, nitrógeno, o azufre con z ocurrencias independientes de -R4, donde z es 0-5; el anillo A es un anillo arilo monocíclico de 5-7 miembros o un anillo arilo bicíclico de 8-10 miembros que tiene 0-3 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno, o azufre, o es un anillo monocíclico de 3-8 miembros saturado o parcialmente no saturado que tiene 0-3 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno, o azufre, donde el anillo A está opcionalmente substituido con y ocurrencias independientes de -R5, donde y es 0-5, y adicionalmente está opcionalmente substituido con q ocurrencias independientes de R5a, donde q es 0-2; x es 0-4; cada ocurrencia de R3, R4, y R5 es independientemente Q-RX; donde Q es una ligadura o es una cadena de alquilideno C1-6 donde hasta dos unidades de metileno no adyacente de Q están reemplazados opcionalmente e independientemente por -NR-, -S-, -O-, -CS-, -CO2-, -OCO-, -CO-, -COCO-, -CONR-, -NRCO-, -NRCO2-, -SO2NR-, -NRSO2-, -CONRNR- , -NRCONR-, -OCONR-, -NRNR-, -NRSO2NR-, -SO-, -SO2-, -PO-, -PO2-, -OP(O)(OR)-, o -POR-; y cada ocurrencia de Rx es seleccionada independientemente entre -R', halógeno, =O, -NR', -NO2, -CN, -OR', -SR', -N(R')2, -NR'COR', -NR'CON(R')2, -NR'CO2R', - COR', -CO2R', -OCOR', -CON(R')2, -OCON(R')2, -SOR', -SO2R', -SO2N(R')2, -NR'SO2R', -NR'SO2N(R')2, -COCOR', -COCH2COR', -OP(O)(OR')2, -P(O)(OR')2, -OP(O)2OR', -P(O)2OR', -PO(R')2, o -OPO(R')2; y cada ocurrencia de R5a es independientemente un grupo alifático C1-6 opcionalmente substituido, halógeno, -OR', -SR', -N(R')2, -NR'COR', -NR'CON(R')2, -NR'CO2R', -COR', -CO2R', -OCOR', -CON(R')2, -OCON(R')2, -SOR', -SO2R', -SO2N(R')2, -NR'SO2R', -NR'SO2N(R')2, -COCOR', -COCH2COR', -OP(O)(OR')2, - P(O)(OR')2, -OP(O)2OR', -P(O)2OR', -PO(R')2, o -OPO(R')2; y cada ocurrencia de R es independientemente hidrógeno o un grupo alifático C1-6 opcionalmente substituido; y cada ocurrencia de R' es independientemente hidrógeno o un grupo alifático C1-6 opcionalmente substituido, un anillo monocíclico de 3-8 miembros saturado, parcialmente no saturado, o completamente no saturado que tiene de 0-3 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno, o azufre, o un sistema de anillo bicíclico de 8-12 miembros saturado, parcialmente no saturado, o completamente no saturado que tiene de 0-5 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno, o azufre; o R y R', dos ocurrencias de R, o dos ocurrencias de R', son tomados conjuntamente con el átomo (los átomos) al cual (a los cuales) están ligados, forman un anillo monocíclico o bicíclico de 3-12 miembros opcionalmente substituido saturado, parcialmente no saturado, o completamente no saturado que tiene de 0-4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno, o azufre; con la condición de que: a. cuando R1 y R2, tomados conjuntamente con el átomo de nitrógeno al cual están ligados, forman un anillo monocíclico de 4 miembros opcionalmente substituido saturado o parcialmente no saturado que tiene 0-3 heteroátomos adicionales independientemente seleccionados entre nitrógeno, azufre, u oxígeno; entonces se excluye 2-oxazolidinona, 3-[(3R,4R)-2-oxo-1-(2-fenil-4- quinazolinil)-4-[2-(3-piridinil)etinil]-3-azetidinil]-4-fenil-, (4S)-; b. cuando R1 y R2, tomados conjuntamente con el átomo de nitrógeno al cual están ligados, forman un anillo monocíclico de 5 miembros opcionalmente substituido saturado o parcialmente no saturado que tiene 0-3 heteroátomos adicionales independientemente seleccionados entre nitrógeno, azufre, u oxígeno; entonces: i. el anillo A no es hexahidro-1H-1,4-diazepin-1-ilo opcionalmente substituido; y ii. se excluyen bencensulfonamida, 2-metoxi-5-[2-[[1-(2-fenil-4-quinazolinil)-3-pirrolidinil]amino]etil]-, (R)-, bis(trifluoroacetato), y bencensulfonamida, 2-metoxi-5-[2-[[1-(2-fenil-4-quinazolinil)-3-pirrolidinil]amino]etil]-, (S)-, bis(trifluoroacetato); iii. se excluyen 3-pirrolidinamina, 1-(2-fenil-4-quinazolinil)-, y (R)-3-pirrolidinamina, 1-(2-fenil-4-quinazolinil)-, (S)-; iv. cuando R1 y R2, tomados conjuntamente son pirrolidin-1-ilo no substituido, el anillo A es fenilo no substituido, y x es 1, entonces R3 no es 6-OMe o 6-OH; v. cuando R1 y R2, tomados conjuntamente son pirrolidin-1-ilo, el anillo A es fenilo no substituido, y x es 2, entonces los dos grupos R3 no son 6-OMe y 7-OMe; vi. cuando R1 y R2, tomados conjuntamente son pirrolidin- 1-ilo no substituido, entonces el anillo A no es pirrolidin-1-ilo no substituido, piperazin-1-ilo opcionalmente substituido, morfolin-1-ilo no substituido; o piperidin-1-ilo no substituido; vii. cuando R1 y R2, tomados conjuntamente son pirrolidin-1- ilo, x es 0 y el anillo A es fenilo no substituido, entonces el grupo pirrolidin-1-ilo no está substituido en la posición 3 con -OH o 2-metoxi-fenoxi; viii. cuando R1 y R2, tomados conjuntamente son pirrolidin-1-ilo no substituido, y x es 0, entonces el anillo A no es 2,3-xililo, 3-metilfenilo, fenilo no substituido, 4-bromo-fenilo, 4-cloro-fenilo, 3-nitro-fenilo, pirid-3-ilo no substituido, 2,4-diclorofenilo, 3,4-diclorofenilo, 4-propoxifenilo, 3-metilfenilo, 3,4,5-trimetoxifenilo, 2- clorofenilo, pirid-4-ilo no substituido, 2-hidroxifenilo, o 4-(1,1-dimetiletil)fenilo; c. cuando R1 y R2, tomados conjuntamente con el átomo de nitrógeno al cual están ligados, forman un anillo monocíclico o bicíclico de 6 miembros opcionalmente substituido saturado o parcialmente no saturado que tiene 0-3 heteroátomos adicionales independientemente seleccionados entre nitrógeno, azufre, u oxígeno; entonces: i. cuando R1 y R2, tomados conjuntamente forman un anillo morfolino no substituido, y el anillo A es fenilo no substituido, entonces x no es 0, o si x es 1 o 2, entonces R3 no es: 6-fluoro, 6,7-dimetoxi, 6-nitro, 6-AcHN-, 6-metox, 6-NH2, 6-OCHN-, 6-OH, 6-AcMeN-, 6-TsHN-, 6-Me2N-, 7-OH, 6-amino-tiazol-2-ilo, 6-NHCOCOOEt, o 6-(4- fenil-amino-tiazol-2-ilo); ii. cuando R1 y R2, tomados conjuntamente forman un anillo morfolino no substituido, y el anillo A es ciclohexilo no substituido, pirid-3-ilo no substituido, 2-furilo no substituido, 2-fluorofenilo, 3-tienilo, benzofurano, piridazina, fenilo substituido en una o más de las posiciones 3, 4, o 5 del anillo fenilo, y x es 1 o 2, entonces R3 no es 6-NH2, 6-OHCHN-, 6-OH, 7-OH, 6-MsHN-, 6-AcHN-, 6-fluoro, o 6-OMe; iii. cuando R1 y R2, tomados conjuntamente, forman piperid-4- ona, piperid-4-ol, o tiomorfolino, o un anillo morfolino dimetil substituido, el anillo A es fenilo no substituido, y x es 1, entonces R3 no es 6-OH; iv. cuando x es 0 y A es fenilo no substituido, 3,4,5-trimetoxifenilo, o 3,4-dimetoxifenilo, entonces R1 y R2, tomados conjuntamente no son piperidinilo opcionalmente substituido o piperazinilo opcionalmente substituido; v. cuando x es 2 o 3, y R3 es 6,7-diOMe, o 6,7,8-triOMe, entonces R1 y R2, tomados conjuntamente no son piperidin-1-ilo opcionalmente substituido, piperazin-1-ilo, o morfolin-1-ilo; vi. cuando x es 0 y el anillo A es fenilo no substituido, entonces R1 y R2 tomados conjuntamente no son piperazinilo opcionalmente substituido o fusionado; vii. cuando x es 0 y el anillo A es fenilo opcionalmente substituido en una o más de las posiciones 3, 4, o 5 del anillo fenilo, entonces R1 y R2, tomados conjuntamente no son piperazin-1-ilo opcionalmente substituido, o morfolin-1-ilo; viii. cuando x es 0 y el anillo A es 2-F- fenilo, entonces R1 y R2, tomados conjuntamente no son 4-(2-Cl-fenil)-piperazin-1-ilo, 4-(3-Cl-fenil)-piperazin-1-ilo, o morfolin-1-ilo no substituido; ix. cuando x es 0 y el anillo A es 2-Cl-fenilo, entonces R1 y R2, tomados conjuntamente no son morfolin-1-ilo no substituido, 4-Me-piperazin-1-ilo, 4-Et-piperazin-1-ilo, 4-fenil-piperazin-1-ilo, o 4-CH2-(fenil)2-piperazin-1-ilo; x. cuando x es 0 y el anillo A es 2-OH-fenilo, entonces R1 y R2, tomados conjuntamente no son morfolin-1-ilo no substituido, 4-(2-OMe-fenil)-piperazin-1-ilo, 4-CH2-fenil-piperazin-1-ilo, 4-Et-piperazin-1-ilo, o 4-Me-piperazin-1-ilo; xi. cuando x es 0, x es 1 y R3 es 6-Br, o x es 2 y R3 es 6-7-diOMe, y el anillo A es 2- o 3-tienilo opcionalmente substituido, entonces R1 y R2, tomados conjuntamente no son 4-fenil-piperazin-1-ilo, 4-(3-CF3-fenil)-piperazin-1-ilo, 4-(2-OEt-fenil)-piperazin-1-ilo, 4-Me-piperazinilo, o morfolin-1-ilo no substituido; xii cuando x es 0, y el anillo A es pirid-3-ilo o pirid-4- ilo no substituido, entonces R1 y R2, tomados conjuntamente no son morfolin-1-ilo opcionalmente substituido, o piperazin-1-ilo opcionalmente substituido; xiii. cuando x es 0, y el anillo A es 1H-imidazol-2-ilo o 1H-imidazol-1-ilo opcionalmente substituido, entonces R1 y R2 tomados conjuntamente no son morfolin-1-ilo no substituido, 4-Me-piperazin-1-ilo, o 4-CH2CH2OH-piperazin-1-ilo; xiv. cuando x es 0 y el anillo A es 5-NO2-tiazol-2-ilo, entonces R1 y R2, tomados conjuntamente no son 4-Me- piperazin-1-ilo; xv. cuando x es 0 y el anillo A es 5-NO2-2-furanilo, entonces R1 y R2, tomados conjuntamente no son 4-CH2CH2OH-piperazin-1-ilo, 4-Me-piperazin-1-ilo, o morfolin-1-ilo no substituido; xvi. cuando x es 1, R3 es 6-OH y el anillo A es fenilo no substituido, entonces R1 y R2, tomados conjuntamente no son morfolin-1-ilo no substituido, o 4-Me-pipe
ARP040100670A 2003-03-03 2004-03-03 Quinazolinas utiles como moduladores de canales ionicos AR044502A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45145803P 2003-03-03 2003-03-03
US46379703P 2003-04-18 2003-04-18

Publications (1)

Publication Number Publication Date
AR044502A1 true AR044502A1 (es) 2005-09-14

Family

ID=32965550

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100670A AR044502A1 (es) 2003-03-03 2004-03-03 Quinazolinas utiles como moduladores de canales ionicos

Country Status (20)

Country Link
US (2) US7678802B2 (es)
EP (1) EP1608632B1 (es)
JP (1) JP5247027B2 (es)
KR (1) KR20050108379A (es)
AR (1) AR044502A1 (es)
AT (1) ATE453629T1 (es)
AU (1) AU2004217891B2 (es)
BR (1) BRPI0408026A (es)
CA (1) CA2517844A1 (es)
CL (1) CL2004000409A1 (es)
DE (1) DE602004024873D1 (es)
ES (1) ES2338553T3 (es)
IL (1) IL170636A (es)
NO (1) NO20054546L (es)
NZ (1) NZ542664A (es)
PE (1) PE20041059A1 (es)
RU (1) RU2378260C2 (es)
TW (1) TW200426147A (es)
UY (1) UY28215A1 (es)
WO (1) WO2004078733A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713983B2 (en) * 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2004092196A2 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
WO2005046698A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
MX2007007446A (es) * 2004-12-17 2008-01-14 Vertex Pharma Procesos para la produccion de 4-aminoquinazolinas.
US8252806B2 (en) * 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
JP5112297B2 (ja) * 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なキノリン誘導体
FR2891829A1 (fr) * 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US8158637B2 (en) 2005-11-14 2012-04-17 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of voltage gated ion channels
JP2009516712A (ja) * 2005-11-23 2009-04-23 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
BRPI0620113A2 (pt) * 2005-12-21 2017-11-21 Painceptor Pharma Corp métodos de modulação da atividade de um canal iônico introduzido, e de tratamento de um distúrbio, e, composto
WO2007115410A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP2024333A2 (en) 2006-04-26 2009-02-18 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
JP2009539988A (ja) * 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
EP2589597B1 (en) * 2006-08-22 2019-03-06 Technion Research & Development Foundation Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR)
CA2665398A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
EP2099458A4 (en) * 2006-12-01 2011-05-11 Harvard College COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR PRESENTATION AND THERAPY
KR20090129488A (ko) * 2007-03-22 2009-12-16 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 ｎ-헤테로사이클릭 화합물
DK2182950T3 (da) * 2007-05-17 2017-11-06 Helperby Therapeutics Ltd Anvendelse af 4-(pyrrolidin-1-yl)quinolinforbindelser til at dræbe klinisk latente mikroorganismer
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
US8324226B2 (en) * 2007-10-24 2012-12-04 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
JP5362839B2 (ja) * 2008-11-14 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３受容体アンタゴニストとしてのキナゾリン誘導体
WO2010135568A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
JP2012527474A (ja) 2009-05-22 2012-11-08 エクセリクシス， インク． 増殖性疾患に対するベンゾキサゼピンベースのｐｉ３ｋ／ｍｔ０ｒ阻害剤
WO2010151595A1 (en) * 2009-06-26 2010-12-29 Schering Corporation Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers
US20110053916A1 (en) 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
PE20121153A1 (es) * 2009-09-03 2012-08-27 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales ionicos de potasio
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
CN105920010A (zh) 2010-12-14 2016-09-07 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
WO2013143319A1 (zh) * 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
CN104395298A (zh) * 2012-06-22 2015-03-04 住友化学株式会社 稠合杂环化合物
WO2014074517A1 (en) 2012-11-08 2014-05-15 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP2970199A1 (en) * 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2015004533A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3062795A4 (en) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103755649A (zh) * 2013-12-31 2014-04-30 李增 一种喹唑啉衍生物及其作为血管生成抑制剂的应用
US9676757B2 (en) * 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
CN106458933B (zh) 2014-04-23 2021-03-05 泰克年研究发展基金会公司 基于喹唑啉支架的化合物、其药物组合物及使用方法
EP3206689B1 (en) * 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10087148B2 (en) * 2014-12-05 2018-10-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health Quinazolines as biogenic amine transport modulators
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
EP3247705B1 (en) * 2015-01-20 2019-11-20 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
WO2017075222A1 (en) * 2015-10-30 2017-05-04 Lieber Institute For Brain Development Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
CA3071534A1 (en) 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
JP7315564B2 (ja) * 2018-02-02 2023-07-26 アジレント・テクノロジーズ・インク グリカン分析のためのブロックされた２－ａａを使用するための方法およびキット
IL280213B2 (en) 2018-07-26 2024-06-01 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CN113316453B (zh) * 2019-01-03 2025-12-23 匹兹堡大学联邦系统高等教育 用于提高转录因子eb多肽水平的方法和材料
US12187681B2 (en) * 2019-12-14 2025-01-07 Shanghai East Hospital Ion channel antagonists/blockers and uses thereof
CA3180317A1 (en) 2020-04-17 2021-10-21 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2024258849A2 (en) 2023-06-13 2024-12-19 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE119051C (es)
NL292083A (es) * 1962-09-18
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US3637693A (en) * 1968-07-12 1972-01-25 Du Pont Hydroxyarylquinazolines and their use as uv-absorbers
US3705898A (en) * 1970-01-26 1972-12-12 Morton Norwich Products Inc Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH612432A5 (es) * 1975-05-12 1979-07-31 Sandoz Ag
US4377582A (en) 1979-12-19 1983-03-22 A. H. Robins Company, Inc. 2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
US4306065A (en) 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JPS56120768A (en) * 1980-01-31 1981-09-22 Ciba Geigy Ag Color developing quinazoline compound
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
DE69425804T2 (de) * 1993-06-17 2001-02-08 Otsuka Pharmaceutical Factory, Inc. Phosphonsäurediesterderivate
JP3722858B2 (ja) * 1993-11-25 2005-11-30 ビーエーエスエフ アクチェンゲゼルシャフト ポリアクリレート溶融体から残留揮発分を除去する方法
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
FR2751656B1 (fr) * 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP4073961B2 (ja) 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
EP0944594A4 (en) 1996-12-13 2000-05-03 Lilly Co Eli INHIBITORS OF THE PSA ANTIGEN ENZYMATIC ACTIVITY
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP3018185B1 (ja) * 1999-02-12 2000-03-13 工業技術院長 キナゾリン誘導体又はその塩の製造方法
JP2001068452A (ja) * 1999-08-26 2001-03-16 Matsushita Electric Ind Co Ltd 回路パターン形成済シリコン基板のエッチング装置およびエッチング方法
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2334858T3 (es) 2000-08-10 2010-03-16 Mitsubishi Tanabe Pharma Corporation Derivados de prolina y uso de los mismos como farmacos.
PL359920A1 (en) * 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
WO2004030672A1 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
TWI289217B (en) * 2004-07-16 2007-11-01 Hon Hai Prec Ind Co Ltd Light guide plate
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) * 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
MX2007007446A (es) 2004-12-17 2008-01-14 Vertex Pharma Procesos para la produccion de 4-aminoquinazolinas.
US8158637B2 (en) 2005-11-14 2012-04-17 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of voltage gated ion channels

Also Published As

Publication number Publication date
JP5247027B2 (ja) 2013-07-24
PE20041059A1 (es) 2005-02-07
JP2006522119A (ja) 2006-09-28
EP1608632B1 (en) 2009-12-30
NO20054546L (no) 2005-11-25
AU2004217891B2 (en) 2011-06-23
US20040248890A1 (en) 2004-12-09
ES2338553T3 (es) 2010-05-10
HK1088314A1 (en) 2006-11-03
US7678802B2 (en) 2010-03-16
CL2004000409A1 (es) 2005-01-07
US20110021495A1 (en) 2011-01-27
UY28215A1 (es) 2004-09-30
AU2004217891A1 (en) 2004-09-16
BRPI0408026A (pt) 2006-02-07
TW200426147A (en) 2004-12-01
US8343980B2 (en) 2013-01-01
KR20050108379A (ko) 2005-11-16
IL170636A (en) 2012-08-30
CA2517844A1 (en) 2004-09-16
WO2004078733A1 (en) 2004-09-16
DE602004024873D1 (de) 2010-02-11
RU2005130486A (ru) 2006-05-10
NZ542664A (en) 2009-03-31
ATE453629T1 (de) 2010-01-15
EP1608632A1 (en) 2005-12-28
RU2378260C2 (ru) 2010-01-10
NO20054546D0 (no) 2005-10-03

Similar Documents

Publication Publication Date Title
AR044502A1 (es) Quinazolinas utiles como moduladores de canales ionicos
RU2434017C2 (ru) Миметики с обратной конфигурацией и относящиеся к ним способы
ES2834027T3 (es) Compuestos de N-pirrolidinil, N'-pirazolil-urea como inhibidores de TrkA quinasa
ES2834333T3 (es) Inhibidores pirimidinil de tirosina quinasa
RU2345996C1 (ru) Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
NO20072116L (no) Farmasoytiske forbindelser
RU2495873C2 (ru) Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
ES2724989T3 (es) Derivados 5-[(piperazin-1-il)-3-oxopropil]imidazolidin-2,4-diona como inhibidores de ADAMTS para el tratamiento de la osteoartritis
NZ731337A (en) Compounds useful as inhibitors of atr kinase
HRP20050944A2 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AR037418A1 (es) Derivados de benzotiazol
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
HUP0400851A2 (hu) Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 II antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200600892A1 (ru) Новые хинолиновые производные
JP2006522119A5 (es)
EP4146654A1 (en) Antagonists of the adenosine a2a receptor
RU99108663A (ru) Производные хиназолина и содержащие их фармацевтические композиции
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
EA012607B1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal